vs
Side-by-side financial comparison of Xiao-I Corp (AIXI) and Cellectis S.A. (CLLS). Click either name above to swap in a different company.
Xiao-I Corp is the larger business by last-quarter revenue ($11.5M vs $9.5M, roughly 1.2× Cellectis S.A.). Xiao-I Corp runs the higher net margin — -263.9% vs -265.9%, a 2.0% gap on every dollar of revenue.
Xiao-i is a Chinese cognitive artificial intelligence enterprise founded in 2001.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
AIXI vs CLLS — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $9.5M |
| Net Profit | $-30.4M | $-25.3M |
| Gross Margin | 58.1% | — |
| Operating Margin | -254.9% | -181.1% |
| Net Margin | -263.9% | -265.9% |
| Revenue YoY | — | 375.0% |
| Net Profit YoY | — | -51.9% |
| EPS (diluted) | — | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $11.5M | — | ||
| Q2 24 | $33.0M | $9.5M | ||
| Q3 23 | — | $1.6M | ||
| Q2 23 | $26.5M | $2.0M | ||
| Q2 22 | — | $2.7M |
| Q2 25 | $-30.4M | — | ||
| Q2 24 | $-15.5M | $-25.3M | ||
| Q3 23 | — | $-17.5M | ||
| Q2 23 | $-18.8M | $-16.6M | ||
| Q2 22 | — | $-19.5M |
| Q2 25 | 58.1% | — | ||
| Q2 24 | 64.5% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 77.3% | 97.3% | ||
| Q2 22 | — | 87.9% |
| Q2 25 | -254.9% | — | ||
| Q2 24 | -45.0% | -181.1% | ||
| Q3 23 | — | -1258.1% | ||
| Q2 23 | -51.5% | -1180.5% | ||
| Q2 22 | — | -1003.0% |
| Q2 25 | -263.9% | — | ||
| Q2 24 | -47.2% | -265.9% | ||
| Q3 23 | — | -1064.1% | ||
| Q2 23 | -70.9% | -831.6% | ||
| Q2 22 | — | -714.4% |
| Q2 25 | — | — | ||
| Q2 24 | $-0.64 | $-0.28 | ||
| Q3 23 | — | $-0.31 | ||
| Q2 23 | $-0.80 | $-0.20 | ||
| Q2 22 | — | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $149.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $148.6M |
| Total Assets | $82.4M | $407.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $5.0M | — | ||
| Q2 24 | $1.8M | $149.0M | ||
| Q3 23 | — | — | ||
| Q2 23 | $4.7M | $84.4M | ||
| Q2 22 | — | $129.4M |
| Q2 25 | — | — | ||
| Q2 24 | — | $148.6M | ||
| Q3 23 | — | $76.1M | ||
| Q2 23 | $525.1K | $96.6M | ||
| Q2 22 | — | $180.5M |
| Q2 25 | $82.4M | — | ||
| Q2 24 | $87.6M | $407.1M | ||
| Q3 23 | — | $209.7M | ||
| Q2 23 | $51.3M | $227.7M | ||
| Q2 22 | — | $320.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $28.9M |
| Free Cash FlowOCF − Capex | — | $27.6M |
| FCF MarginFCF / Revenue | — | 290.5% |
| Capex IntensityCapex / Revenue | — | 13.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-2.3M | — | ||
| Q2 24 | — | $28.9M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.4M | ||
| Q2 22 | — | $-60.2M |
| Q2 25 | — | — | ||
| Q2 24 | — | $27.6M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-47.9M | ||
| Q2 22 | — | $-61.7M |
| Q2 25 | — | — | ||
| Q2 24 | — | 290.5% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -2391.4% | ||
| Q2 22 | — | -2266.7% |
| Q2 25 | — | — | ||
| Q2 24 | — | 13.2% | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 24.1% | ||
| Q2 22 | — | 56.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
